Aktienanalyse zu Talphera Inc (TLPH)TLPHTalphera Inc

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Talphera Inc (TLPH) is a good buy right now due to its current price of $1.20, which is significantly below the analyst price target of $3, suggesting a potential upside of 150%. Additionally, the forward P/E ratio of 1.0172 indicates that the stock is undervalued relative to its future earnings potential. The main risk is the negative net income, which was -$4,312,000 in Q2 2026, indicating ongoing financial challenges.